Clinical response after guselkumab treatment among adalimumab PASI 90 nonresponders: Results from the VOYAGE 1 and 2 trials - 03/08/18
Christopher E.M. Griffiths, MD, Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre; Marc Alexander Radtke, MD, Universitaetsklinik Hamburg-Eppendorf; Sang Woong Youn, MD, PhD, Seoul National University College of Medicine, Bundang Hospital; Robert Bissonnette, MD, Innovaderm Research; Michael Song, MD, Janssen Research and Development; Yasmine Wasfi, MD, PhD, Janssen Research and Development; Bruce Randazzo, MD, PhD, Janssen Research and Development; Yin You, PhD, Janssen Research and Development; Yaung-Kaung Shen, PhD, Janssen Research and Development; Bruce Strober, MD, PhD, University of Connecticut Health Center
Le texte complet de cet article est disponible en PDF.| Commercial support: Janssen Research and Development, LLC. |
Vol 79 - N° 3S1
P. AB78 - septembre 2018 Retour au numéro
Article précédent
- Clinical manifestations, management, and diagnostic techniques used in hematopoietic stem cell transplant patients with skin infections: A five-year review
- Cocaine-induced pyoderma gangrenosum–like lesions: Levamisole may be not the only culprit. Report of three cases and review of the literature
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?